MRNA Latest Headlines

Moderna’s Surprise Surge: Is the mRNA Giant Back?

at www.tipranks.com (Sat, 27-Jun 10:02 AM)

Why Moderna (MRNA) Stock Is Soaring Today – June 26, 2026

at www.tipranks.com (Fri, 26-Jun 2:37 PM)

Moderna stock soars 15% as bulls cheer drug pipeline update: Next stop $75?

at seekingalpha.com (Fri, 26-Jun 1:42 PM)

Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms

at seekingalpha.com (Fri, 26-Jun 12:22 PM)

Lilly, J&J, AbbVie hit new 52-week highs as healthcare outperforms

at seekingalpha.com (Fri, 26-Jun 12:22 PM)

Moderna Maintained at Hold as Analyst Weighs Leading mRNA Platform Against Early-Stage Pipeline Risks

at www.tipranks.com (Fri, 26-Jun 9:05 AM)

Hold Rating Reiterated on Moderna as Analyst Keeps $49 Price Target Amid Long-Term Pipeline Potential and Near-Term Execution Risks

at www.tipranks.com (Fri, 26-Jun 8:35 AM)

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Edwards Lifesciences (EW), Encompass Health (EHC) and Moderna (MRNA)

at www.tipranks.com (Fri, 26-Jun 7:30 AM)

Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Vaxcyte (PCVX)

at www.tipranks.com (Fri, 26-Jun 7:00 AM)

Hold Rating Reaffirmed on Moderna as Analyst Highlights High-Risk/High-Reward Pipeline and Keeps Price Target Unchanged at $41

at www.tipranks.com (Fri, 26-Jun 6:25 AM)

Analyst Maintains Sell on Moderna as Shares Trade Above Unchanged $34 Price Target Despite Scientific Momentum

at www.tipranks.com (Fri, 26-Jun 5:25 AM)

Moderna Expands mRNA Platform Potential with T-Cell Engagers, CAR-T Program, and Cancer Prevention Initiatives

Market Chameleon (Thu, 25-Jun 8:36 AM)

What’s next in line for FDA reversals after UniQure and Regenxbio

at seekingalpha.com (Wed, 24-Jun 12:38 PM)

Moderna’s Upcoming Science Day Shines Spotlight on R&D Acceleration Through AI and Robotics

Market Chameleon (Wed, 17-Jun 7:30 AM)

mRNA Cancer Immunotherapy Shows Early Promise as Platform Approaches Gain Traction in Biotech

Market Chameleon (Mon, 11-May 11:49 AM)

Moderna’s mRNA-1010 Flu Vaccine Shows Superior Efficacy in Phase 3 Study—Regulatory Filings Underway Across Four Continents

Market Chameleon (Thu, 7-May 7:13 AM)

Moderna’s Revenue Surges on International Strength and New Vaccine Approvals as Cost Discipline Deepens

Market Chameleon (Fri, 1-May 7:07 AM)

MRNA Fast Track: mRNA-4359 & Pembrolizumab Show 83% Response Rate in First-Line Melanoma Study

Market Chameleon (Mon, 20-Apr 8:13 AM)

Moderna Highlights Encouraging Revaccination Data for Influenza and RSV Vaccines Ahead of Major Regulatory Decisions

Market Chameleon (Tue, 7-Apr 8:32 AM)